Paradigm Biocapital Advisors LP Buys 1,115,412 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Paradigm Biocapital Advisors LP increased its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 46.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 3,515,986 shares of the company's stock after buying an additional 1,115,412 shares during the period. Janux Therapeutics comprises approximately 6.5% of Paradigm Biocapital Advisors LP's holdings, making the stock its 5th biggest position. Paradigm Biocapital Advisors LP owned 6.70% of Janux Therapeutics worth $188,246,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Lester Murray Antman dba SimplyRich grew its position in Janux Therapeutics by 205.3% in the 4th quarter. Lester Murray Antman dba SimplyRich now owns 24,315 shares of the company's stock worth $1,301,000 after purchasing an additional 16,351 shares during the last quarter. abrdn plc bought a new position in Janux Therapeutics in the 4th quarter worth about $3,430,000. Barclays PLC boosted its holdings in shares of Janux Therapeutics by 496.5% in the third quarter. Barclays PLC now owns 174,061 shares of the company's stock valued at $7,907,000 after acquiring an additional 144,883 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of Janux Therapeutics by 45.3% in the fourth quarter. Legal & General Group Plc now owns 34,540 shares of the company's stock valued at $1,849,000 after acquiring an additional 10,776 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Janux Therapeutics by 1.6% in the fourth quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock valued at $2,043,000 after acquiring an additional 599 shares in the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the firm's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $30.00, for a total transaction of $100,020.00. Following the transaction, the insider now owns 82,139 shares in the company, valued at approximately $2,464,170. This trade represents a 3.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ra Capital Management, L.P. purchased 341,742 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were acquired at an average price of $30.64 per share, for a total transaction of $10,470,974.88. Following the acquisition, the director now directly owns 9,658,988 shares in the company, valued at $295,951,392.32. This represents a 3.67% increase in their position. The disclosure for this purchase can be found here. Insiders sold 10,001 shares of company stock valued at $313,964 in the last three months. Corporate insiders own 8.10% of the company's stock.

Janux Therapeutics Trading Down 1.1%

JANX stock traded down $0.27 during midday trading on Monday, reaching $24.01. The company had a trading volume of 362,004 shares, compared to its average volume of 867,007. Janux Therapeutics, Inc. has a 1 year low of $22.48 and a 1 year high of $71.71. The company has a market capitalization of $1.42 billion, a P/E ratio of -20.52 and a beta of 3.24. The company has a 50 day moving average of $28.66 and a two-hundred day moving average of $40.54.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Scotiabank decreased their price objective on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a report on Friday, February 28th. Wedbush reiterated an "outperform" rating and issued a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Finally, HC Wainwright reissued a "buy" rating and set a $70.00 target price on shares of Janux Therapeutics in a research note on Monday, March 3rd. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, Janux Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $95.25.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.